By evaluating the data from RCTs in RMS patients, significant differences in the percentage brain volume change (PBVC) (SIENA software) from week 24 to week 96 between the ocrelizumab- and the IFN -1a group were observed in the OPERA I (PBVC = 0.57% vs 0.74%, 22.8% difference, p = 0.004), but not in the OPERA II (PBVC = 0.64% vs 0.75%, 14.9% difference, p = 0.09) [2]
Lang F, Gulbins E, Lerche H, Huber SM, Kempe DS, Foller M
For many people, theyve been transformative for metabolic health but if youre planning to conceive, whether naturally or through fertility treatments like IVF, there are important considerations for GLP-1 use in proximity to conception
This plays a vital role in nerve development and signal transmission
For individuals with obesity but no diabetes, GLP-1 therapy increased health care costs with no significant reduction in obesity-related health issues over two years
Please scroll down to read further